Technical Analysis for GHRS - GH Research PLC
Grade | Last Price | % Change | Price Change |
---|---|---|---|
B | 11.99 | -0.75% | -0.09 |
GHRS closed down 0.75 percent on Wednesday, May 8, 2024, on 35 percent of normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions.
Earnings due: May 15
*** please verify all earnings dates ***ADX | Long Term | Intermediate Term | Short Term |
---|---|---|---|
Strong | Up | Up | Up |
Date | Alert Name | Type | % Chg |
---|---|---|---|
Boomer Buy Setup | Bullish Swing Setup | 0.00% | |
NR7 | Range Contraction | 0.00% | |
Narrow Range Bar | Range Contraction | 0.00% | |
Upper Bollinger Band Walk | Strength | 0.00% | |
Inside Day | Range Contraction | 0.00% | |
180 Bullish Setup | Bullish Swing Setup | -0.75% | |
Boomer Buy Setup | Bullish Swing Setup | -0.75% | |
Pocket Pivot | Bullish Swing Setup | -0.75% | |
Upper Bollinger Band Walk | Strength | -0.75% | |
Inside Day | Range Contraction | -0.75% |
Alert | Time |
---|---|
Possible NR7 | about 11 hours ago |
Possible Inside Day | about 11 hours ago |
Down 2 % | about 12 hours ago |
Down 1% | about 12 hours ago |
60 Minute Opening Range Breakdown | about 13 hours ago |
Get a Trading Sidekick!
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: 05/15/2024
GH Research PLC, a clinical-stage biopharmaceutical company, engages in developing various therapies for the treatment of psychiatric and neurological disorders. The company focuses on developing 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) therapies for the treatment of patients with treatment-resistant depression (TRD). Its lead program is GH001, an inhalable 5-MeO-DMT product candidate that is being investigated in the Phase 2 part of an ongoing Phase 1/2 clinical trial in patients with TRD. The company also develops GH002, an injectable 5-MeO-DMT product candidate that is in preclinical development trials with a focus on psychiatric and neurological disorders. GH Research PLC was founded in 2018 and is based in Dublin, Ireland.
Sector: Healthcare
Industry: Biotechnology
Keywords: Biopharmaceutical Psychoactive Drugs Entheogens Treatment Resistant Depression Psychiatric And Neurological Disorders N Dimethyltryptamine
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Biopharmaceutical Psychoactive Drugs Entheogens Treatment Resistant Depression Psychiatric And Neurological Disorders N Dimethyltryptamine
Indicator | Bull Case | Neutral / Hold | Bear Case |
---|---|---|---|
50 DMA | |||
200 DMA | |||
ADX Trend | |||
Oversold / Overbought | |||
Relative Strength |
Indicator | Value |
---|---|
52 Week High | 14.64 |
52 Week Low | 5.05 |
Average Volume | 104,720 |
200-Day Moving Average | 8.90 |
50-Day Moving Average | 10.54 |
20-Day Moving Average | 11.28 |
10-Day Moving Average | 11.33 |
Average True Range | 0.69 |
RSI (14) | 60.47 |
ADX | 42.24 |
+DI | 26.35 |
-DI | 8.69 |
Chandelier Exit (Long, 3 ATRs) | 10.32 |
Chandelier Exit (Short, 3 ATRs) | 12.37 |
Upper Bollinger Bands | 12.20 |
Lower Bollinger Band | 10.35 |
Percent B (%b) | 0.89 |
BandWidth | 16.38 |
MACD Line | 0.35 |
MACD Signal Line | 0.30 |
MACD Histogram | 0.0463 |
Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
---|---|---|---|---|---|
Resistance 4 (R4) | 12.43 | ||||
Resistance 3 (R3) | 12.43 | 12.28 | 12.36 | ||
Resistance 2 (R2) | 12.28 | 12.16 | 12.28 | 12.33 | |
Resistance 1 (R1) | 12.13 | 12.09 | 12.06 | 12.14 | 12.31 |
Pivot Point | 11.98 | 11.98 | 11.94 | 11.98 | 11.98 |
Support 1 (S1) | 11.84 | 11.87 | 11.76 | 11.84 | 11.67 |
Support 2 (S2) | 11.69 | 11.80 | 11.69 | 11.65 | |
Support 3 (S3) | 11.54 | 11.69 | 11.62 | ||
Support 4 (S4) | 11.55 |